PI: Helmut Bischof
Focus: We are dedicated to studying the interactions between cancer cells and immune cells, with a particular focus on cytotoxic T cells. This specific subgroup of the immune system is capable of recognizing and eliminating tumor cells. However, despite this natural defense capability, cancer cells often manage to evade these T cells and protect themselves from the lethal cytotoxic reaction. Our team investigates how these protective mechanisms can be overcome to make cancer cells vulnerable again and to activate the body’s own immune response.
A central aspect of our research is the analysis of intercellular communication and exchange processes that contribute to cancer progression or the development of resistance to immune defenses.
By applying approaches at the molecular, (sub)cellular, and systemic levels in clinically relevant samples and preclinical models, we ultimately aim to identify target structures in the fight against cancer, develop new therapeutic strategies, and translate these findings into patient-related samples for validation.
Network: To comprehensively address these research topics, we work closely with local and international partners. The collaboration with colleagues from the Division of Oncology provides a fundamental basis for the research questions being addressed.
This project investigates how phenol-rich formulations from native Nigerian medicinal plants can increase the potential for fighting cancer. We extract and analyze their effect on breast cancer cells in vitro and in vivo. In doing so, we investigate how the formulations modulate molecular targets in order to develop more effective and less toxic cancer therapies.
This project aims to investigate how potassium ion (K⁺) balance influences cancer cells, as it plays a key role in cancer metabolism. Using genetically encoded K⁺ sensors and breast cancer cell models, we measure K⁺ dynamics, specifically alter the K⁺ profile, and correlate this with metabolism and malignancy. Our findings will lead to new, personalized diagnostic and therapeutic strategies.
This project investigates why TNBC cells are resistant to cytotoxic T cells (ZTZn). We analyze TNBC cell lines and patient-derived cells for differences in apoptosis and immune markers to understand resistance mechanisms and develop new immunotherapy strategies.
Investigating (sub)cellular K+ concentrations and dynamics in cancer cells, funded by the Alexander von Humboldt Foundation
